采用CHOP化疗，随后CHOP与利妥昔单抗联合治疗，成功治愈了瓦尔登斯特伦巨球蛋白血症后的弥漫性大B细胞淋巴瘤。

Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.

作者信息

Uchino Keita, Sameshima Hidekazu, Miyamoto Toshihiro, Iino Tadafumi, Kato Koji, Henzan Hideho, Aoki Ken-ichi, Nagafuji Koji, Gondo Hisashi, Harada Mine

机构信息

Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582.

出版信息

Intern Med. 2004 Feb;43(2):131-4. doi: 10.2169/internalmedicine.43.131.

DOI:10.2169/internalmedicine.43.131

PMID:15005256

Abstract

We report a 72-year-old man with Waldenström's macroglobulinemia (WM) in whom diffuse large B-cell lymphoma (DLCL) occurred 17 years after the diagnosis of WM. The malignant cells of both DLCL and WM expressed CD20 on their surface. CHOP plus anti-CD20 monoclonal antibody, rituximab, were effective for both diseases, and the patient remains disease-free 17 months later.

摘要

我们报告了一名72岁患有华氏巨球蛋白血症（WM）的男性，其在WM诊断17年后发生了弥漫性大B细胞淋巴瘤（DLCL）。DLCL和WM的恶性细胞表面均表达CD20。CHOP方案加抗CD20单克隆抗体利妥昔单抗对这两种疾病均有效，17个月后该患者仍无疾病。